Bristol’s $14 Billion Karuna Deal Highlights Race for New Drugs
Bloomberg Businessweek
Bristol Myers Squibb's $14 Billion Acquisition of Karuna Therapeutics
This chapter discusses the news of Bristol Myers Squibb acquiring Karuna Therapeutics for $14 billion, highlighting the race among drug makers to expand their portfolio. It explores the implications of the deal, the competitive process involved, and potential areas of interest for drug makers. The chapter also discusses the prospects of M&A activity in the biotech sector and the broader market going forward.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
